CNS-optimized biguanides for neurodevelopmental disorders.

Pano Therapeutics is developing PAN1195, an oral, once-daily CNS-optimized biguanide designed to redirect a clinically validated pharmacology class into the brain — with Fragile X Syndrome as the lead indication and a biomarker-driven path across a broader cluster of syndromic neurodevelopmental disorders.